AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01987479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Biologic DMARDs
Description: Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
Study NCT01987479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
Study NCT01987479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered per investigator's discretion.
Study NCT00143923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition, Exercise, Stress Management Counseling
Description: Individualized advice
Study NCT00143923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: usual care
Study NCT02409680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Description: Daily administration of low dose (81 mg) aspirin \[also known as acetylsalicylic acid (ASA\], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
Study NCT01138293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motion detection with a motion sensor
Description: To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
Study NCT03223740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1 pre-operative chemoradiation
Description: Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29.
Study NCT03223740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 post operative chemoradiation
Description: Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29
Study NCT02409680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06067763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
Study NCT06067763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
Study NCT06067763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Weight of the Nation
Description: This 2012 documentary discusses the facts and myths about obesity and the impacts of obesity on individuals and the health care system in the United States.
Study NCT04330456 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic radiation therapy in hypofractionation mode
Description: At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy.
Study NCT04330456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
Study NCT02647827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle management
Description: All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
Study NCT02647827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
Study NCT02647827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
Study NCT04129229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LinguaFlex Tongue Retractor (LTR)
Description: The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
Study NCT06697132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic dismembered pyeloplasty
Description: Modified antegrade stenting in laparoscopic pediatric pyeloplasty
Study NCT04330456 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative conformal radiation therapy in normofractionation mode
Description: In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery.
Study NCT02202161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
Study NCT03295981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
Study NCT03363386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proprioceptive Exercises
Description: Patients trained for proprioceptive exercises
Study NCT03363386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resistive Exercises
Description: Patients trained for resistive exercises
Study NCT03363386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Patients were educated with treadmill walking for 30 minutes of each exercise session
Study NCT03363386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Patients were educated with treadmill walking for 30 minutes of each exercise session
Study NCT04277143 — intervention group
Intervention type: DRUG
Intervention: Daptomycin
Description: Adult patients are given the recommended dose of daptomycin for injection. Patients with creatinine clearance (CLCR) ≥ 30 mL / min: 6 mg / kg every 24 hours.~Patients with creatinine clearance (CLCR) \<30mL / min (including hemodialysis or peritoneal dialysis): 6mg / kg every 48 hours. Dissolve 6mg / kg of this drug in 0.9% sodium chloride injection and instill it over a 30-minute time course once every 24 or 48 hours.
Study NCT01860677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fisher Wallace Cranial Stimulator
Description: The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
Study NCT02415049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental Feeds
Description: This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
Study NCT02415049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad lib feeds
Description: This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
Study NCT00120081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-ASP-2/Alhydrogel Hookworm Vaccine
Description: The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
Study NCT00120081 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Inactive saline placebo control
Study NCT02660593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SanGrow Decoction
Description: SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
Study NCT01120470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
Study NCT01120470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
Study NCT01120470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
Study NCT04109807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: ozone exposure
Study NCT04109807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FA
Description: Filtered air exposure
Study NCT03076216 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OncoSil™
Description: The implantation of OncoSil™ under EUS
Study NCT01884506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled iron solution
Description: labeled iron as ferrous sulfate (6mg/test meal)
Study NCT02202161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
Study NCT02202161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
Study NCT02202161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
Study NCT01860677 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fisher Wallace Cranial Stimulator
Description: The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
Study NCT04460560 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Terlipressin
Description: For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump
Study NCT05200000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SygeLIX-Coll-T
Description: Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
Study NCT00670163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Partner Therapy (EPT)
Description: EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
Study NCT00670163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communidades Positivas (CPOS)
Description: The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
Study NCT00670163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care will consist of usual care for STIs.
Study NCT04395144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake Prone Positioning
Description: Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
Study NCT04395144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients will not receive any special instructions with regards to proning.
Study NCT01639196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassion writing
Description: Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
Study NCT01639196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-efficacy writing
Description: Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
Study NCT01884506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled iron solution and ascorbic acid
Description: labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
Study NCT03118856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of Histology
Description: The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
Study NCT02512874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Rehabilitation
Description: Measures of frailty taken before and after pulmonary rehabilitation.
Study NCT02512874 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamometer
Description: Grip Test
Study NCT02512874 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA
Description: Body Composition Testing
Study NCT02512874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gait Speed Test
Description: 15 foot walk test
Study NCT02512874 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Activity Monitor
Description: Measures energy expenditure and activity
Study NCT02512874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
Study NCT02026739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high supplemental oxygen concentration (conventional)
Description: high supplemental oxygen concentration would be used during the surgery
Study NCT04826432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.9 MG/ML
Description: 0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
Study NCT04826432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline water
Description: 0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
Study NCT01336764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal and breathing retraining
Description: They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
Study NCT01336764 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Unguided listening to radio/music.
Study NCT01357733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early interim FDG PET/CT after 1 cycle of R-CHOP
Description: FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
Study NCT04873505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: troches
Description: Take one troche after each meal.
Study NCT04873505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: troches
Description: Take one troche after each meal.
Study NCT03962010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-G6
Description: long acting anti-diabetic drug
Study NCT02202161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
Study NCT02202161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
Study NCT04022291 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humulin ®70/30
Description: Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli.